Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04361357
Other study ID # zhangyan
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 5, 2020
Est. completion date December 31, 2022

Study information

Verified date February 2020
Source Xuanwu Hospital, Beijing
Contact Yan Zhang, MD
Phone 0086-13671376710
Email zhangylq@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The incidence of malnutrition in patients with severe neurological diseases is approximately 37%, among which hypoproteinemia is a common manifestation. It has been confirmed that serum albumin level is closely related to severity and mortality for patients. Protein is the basic component of tissue cells in the body, which plays an important role in the growth and development of senescent cells and the repair of damaged tissues. At present, the results of some randomized controlled studies show that it is difficult to achieve enough protein supplementation by commercial standard enteral nutrition agents alone, and additional protein supplementation is required. Commercial standard enteral nutrition preparations, whose whole protein components are casein and soy protein, do not achieve optimal uptake and utilization compared to whey proteins, which are more readily absorbed and utilized by the human gut. Whey protein and its hydrolyzed products have better nutritional quality than casein, which can provide high-quality nitrogen source for enteral nutrition and play an important role in correcting negative nitrogen balance, promoting wound healing and improving body immunity. Whether whey protein supplementation based on standard enteral nutrition preparation can improve serum albumin level and reduce the incidence of hypoproteinemia in patients with severe acute neurological disease has not been proved. In conclusion, we propose the hypothesis that compared with the standard enteral nutrition preparation regimen, the enteral nutrition regimen supplemented with whey protein in patients with severe neurological disease is more beneficial to improve the nutritional indicators of patients and reduce the occurrence of hypoproteinemia. It is expected that this randomized controlled trial will provide a new clinical basis for optimizing the enteral nutrition support program for patients with severe neurological diseases.


Description:

The purpose of the study is to compare standard enteral nutrition regimen with the enteral nutrition regimen supplemented with whey protein in severe neurological disease patients and to observe nutritional indicators improvement in these patients. A total of 116 subjects will be included. Counting process is as follows: referring available literature and the mean value of serum albumin in patients on the 14th day of our preliminary tests, and the difference test is used to compare the mean values of two independent samples. The ratio of the experimental group and control group is 1:1. It was assumed that the serum albumin level in the experimental group was higher than that in the control group. A single end is taken, α=0.05, 1-β=0.80, experimental group patients serum albumin(Χ±S)=37.9±5.1, the control group serum albumin(Χ±S)=35.6±4.8, so the total sample size was 116.It was estimated that 116 patients were enrolled consecutively, which were divided into experimental group and control group by computer generated random number table. Patients in both groups received enteral nutrition therapy with continuous tube feeding for 14 days. According to the nutritional treatment requirements of critically ill patients in the Asia-Pacific region in 2016, patients with severe acute stress were given energy demand for 25~30kcal/kg/d, protein demand for 1.2~2g/kg/d and other standardized clinical treatments. Control group nutrition program: standardized enteral nutrition preparation only. Experimental group nutrition program: whey protein powder was added on the basis of standardized enteral nutrition preparation. According to the body weight of the patients, different enteral nutritional preparations and dose adjustments were selected to ensure that the calorie and protein intake of the two groups of patients met the above nutritional treatment requirements.Primary endpoint: serum albumin level at 14 days of enteral nutrition. Secondary end points: 1. APACHE II, GCS and other clinical scores at 14 days; 2. total serum protein, proalbumin, hemoglobin and other nutritional indicators; 3. the number and ratio of white blood cells, neutrophils, c-reactive protein, interleukin-6, procalcitonin, absolute count of T lymphocyte subsets, immunoglobulin and other inflammatory indicators at 14 days; 4. the number of cases of gastrointestinal complications such as gastric retention, vomiting, diarrhea, abdominal distention, constipation and gastrointestinal bleeding during the 14 days of enteral nutrition; 5. the number of patients with serum albumin < 30g/L within 14 days after admission.


Recruitment information / eligibility

Status Recruiting
Enrollment 116
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Clinical diagnosis of severe neurological Disease 2. Serum albumin =30g/L 3. Weight: 50~90kg 4. Nutrition risk screening 2002 (NRS2002) =3 points 5. Acute gastrointestinal function injury (acute gastrointestinal injury, AGI) class 1~2 6. Expected enteral nutrition in tube feeding for at least 14 days 7. Obtain the informed consent of the patient or its authorized client Exclusion Criteria: 1. Pregnant and breast-feeding women 2. Serious heart, lung and other important organ function injury 3. Malignant tumor 4. Hypothermia treatment 5. BMI=28 6. Allergic to milk 7. Receiving parenteral nutritional support therapy 8. APACHE II =30

Study Design


Intervention

Other:
whey protein
whey protein powder was added on the basis of standardized enteral nutrition preparation.

Locations

Country Name City State
China Xuanwu Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The number of gastrointestinal complications such as gastric retention, vomiting, diarrhea, abdominal distention, constipation and gastrointestinal bleeding During the 14 days of enteral nutrition
Primary Serum albumin level At 14 days of enteral nutrition
Secondary Serum proalbumin level At 14 days of enteral nutrition
See also
  Status Clinical Trial Phase
Completed NCT03438942 - Influence of Iron and Foliate Transporters on Bioavailability of These Micronutrients in the Organism N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Recruiting NCT02763878 - Uncut Roux-en-y Anastomosis Reduce Postoperative Complication and Improve Nutritional Status After Distal Gastrectomy Phase 3
Completed NCT02402985 - Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics N/A
Completed NCT02039596 - Nutritional Metabolomics: the Search for Dietary Exposure Variables N/A
Active, not recruiting NCT00996528 - Neighborhood Alcohol & HIV Prevention in South African Townships (Philani) Phase 3
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Active, not recruiting NCT03843424 - Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers N/A
Recruiting NCT05348590 - Phase-Germ Project: Muscle Mass and Phase Angle in Surgical Patient
Completed NCT03440593 - Indirect Calorimetry Usage and Effect in Ventilator-free Days and Muscle Thickness in Septic Ventilated Patients N/A
Recruiting NCT04554758 - Comparative Analysis Between Sleeve Gastrectomy and Roux-en Y Gastric Bypass in Bariatric Operation N/A
Recruiting NCT04389424 - Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Completed NCT01708681 - Lean Seafood Intake and Postprandial Metabolism N/A
Completed NCT01211301 - Medifast 5 & 1 Plan N/A
Completed NCT01081587 - Preventing Malnutrition and Restoring Nutritional Status in Hospitalized Children N/A
Active, not recruiting NCT03865706 - Inulin for Infections in the Intensive Care Unit Phase 2
Recruiting NCT05276752 - Short- and Long-term Health Adverse Outcomes Associated With Nutrition Disorders and Nutrition Related Conditions in Hospitalized Older People
Recruiting NCT03643341 - Family Healthy Living Early Intervention Program N/A
Not yet recruiting NCT03618329 - Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM. N/A